Preclinical Services

FAQs

• What are Revvity’s Preclinical Services?

  Revvity provides a suite of preclinical CRO services to support drug discovery, specializing in cell-based assays for oncology and immunology. These services include mechanism of action and pathway analysis, target identification and validation, phenotypic and functional screening, synthetic lethality profiling, and drug sensitivity, resistance and combination studies. We can also generate large, high quality drug response data sets to train and validated drug discovery AI models.  

  In addition, we offer services from our Revvity Gene Delivery team for viral vector engineering and manufacturing, with custom solutions and innovative technologies for cost-effective, quality production, and comprehensive support.

• Who are Revvity’s Preclinical Services designed for?

  Our preclinical services support biotechnology and pharmaceutical organizations worldwide to gain competitive advantages through data quality, scientific rigor, collaboration, accelerated timelines, and strategic resource optimization. 

  Whether you're filling critical capability gaps or outsourcing specialized projects, we work as an extension of your research team to meet project timelines and improve your therapeutic development ROI.

• What therapeutic areas does Revvity’s Preclinical Services specialize in?

  Drawing on nearly two decades of experience, Revvity’s preclinical services team delivers high‑throughput oncology screening, cell panel screening, functional genomic screening, immune cell screening, CRISPR‑based screens, and access to over 600 cell lines. Through close collaboration, we help teams answer a variety of drug discovery questions - from what is the right target to what the genetic drivers are and identifying drug delivery mechanisms. If timing is critical to your program's success, we can work to accelerated schedules, so you don’t have to choose between speed and scientific excellence.

  Our preclinical services team has deep expertise in cell‑based assays for oncology and immuno‑oncology. We use cutting-edge platforms to support multiple therapeutic modalities, including small molecules, biologics, ADCs, and oligo-based therapeutics, giving you the versatility to pursue multiple opportunities simultaneously. 

  As part of Revvity, our preclinical services team has unique access to the full breadth of our reagent, instrumentation, and software portfolio to solve your challenges. From high-content screening with the Opera Phenix™ HCS system to biomarker detection with AlphaLISA™, HTRF™, and LEGENDplex™ assays, and precise liquid handling with the FlexDrop™ non-contact dispenser, we can combine best-in-class tools with deep scientific expertise to accelerate your path from question to insight.

  With our viral vector services from our Revvity Gene Delivery team, we specialise in cell and gene therapy using AAVs and lentiviral vectors delivered to rigorous quality standards.

• What types of readouts and technologies are available?

  We offer a wide range of readouts, including high‑content imaging using the Opera Phenix™ Plus HCS system, HTRF™, AlphaLISA™, LEGENDplex™, ATPlite assays, genomics, transcriptomics, single cell, and flow cytometry.  

  The quality data we provide represents the competitive intelligence you need for robust phenotypic, functional, and mechanistic insights that drive critical decisions and can accelerate your program's success.

• Can Revvity’s Preclinical Services support custom assay development?

  Yes, we support custom and bespoke projects, including assay development, unique cell types, and co‑culture systems tailored to your scientific questions. 

  We work collaboratively with your team – you have direct access to our research scientists throughout your program, giving you control over assay design and progress.

• How can Revvity’s Preclinical Services accelerate oncology drug discovery timelines?

  With nearly two decades of experience, we deliver results that matter: high-throughput oncology screening, cell panel screening, functional genomic screening, immune cell screening, CRISPR-based screens, and access to 600+ validated cell lines. 

  We don't just answer your drug discovery questions - we work closely with your team to identify breakthrough targets, uncover genetic drivers, optimize drug delivery mechanisms, and deliver quality data and actionable insights. 

• Why choose Revvity as your preclinical CRO partner?

  Revvity delivers preclinical CRO services to help fast-track your drug discovery success. With nearly two decades of expertise, we specialize in high-impact cell-based assays for oncology and immunology that generate the actionable data you need to make confident go/no-go decisions. 

  Competitive advantage can come down to timing, so we've built our operations around flexibility and can work to expedited delivery schedules to meet your project timelines.

  When you partner with us, you work directly with our research scientists throughout your program, allowing close collaboration and control over assay design and progress. 

  Our viral vector services from the Revvity Gene Delivery team provide engineering and manufacturing capabilities with innovative technologies that help lower costs while delivering quality outcomes and comprehensive support.

• How do I get started working with Revvity’s Preclinical Services?

  Contact our preclinical services team today to discuss how we can fast-track your project, schedule a consultation, and identify the optimal service model to support your drug discovery strategy.